Immunic Stock Rated Outperform by Wedbush Analysts
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowWedbush has initiated coverage of Immunic, Inc. with an Outperform rating. This rating suggests potential for growth in the company’s stock performance. Immunic is a clinical-stage biopharmaceutical company focused on innovative therapeutics. This move could attract investor interest in Immunic (IMUX), influencing its market performance.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
